Cost-effectiveness thresholds (CETs) based on the Commission on Macroeconomics and Health (CMH) are extensively used in low-and middle-income countries (LMICs) lacking locally defined CETs. These thresholds were originally intended for global and regional prioritization, and do not reflect local context or affordability at the national level, so their value for informing resource allocation decisions has been questioned. Using these thresholds, rotavirus vaccines are widely regarded as cost-effective interventions in LMICs. However, high vaccine prices remain a barrier towards vaccine introduction. This study aims to evaluate the cost-effectiveness, affordability and threshold price of universal rotavirus vaccination at various CETs in Malaysia. Cost-effectiveness of Rotarix and RotaTeq were evaluated using a multi-cohort model. Pan American Health Organization Revolving Fund's vaccine prices were used as tender price, while the recommended retail price for Malaysia was used as market price. We estimate threshold prices defined as prices at which vaccination becomes cost-effective, at various CETs reflecting economic theories of human capital, societal willingness-to-pay and marginal productivity. A budget impact analysis compared programmatic costs with the healthcare budget. At tender prices, both vaccines were cost-saving. At market prices, cost-effectiveness differed with thresholds used. At market price, using 'CMH thresholds', Rotarix programmes were cost-effective and RotaTeq were not cost-effective from the healthcare provider's perspective, while both vaccines were cost-effective from the societal perspective. Using other CETs, both vaccines were not cost-effective at market price, from the healthcare provider's and societal perspectives. At tender and cost-effective prices, rotavirus vaccination cost $1 and 3% of the public health budget, respectively. Using locally defined thresholds, rotavirus vaccination is cost-effective at vaccine prices in line with international tenders, but not at market prices. Thresholds representing marginal productivity are likely to be lower than those reflecting human capital and individual preference measures, and may be useful in determining affordable vaccine prices.
Introduction
Decision-makers increasingly rely on cost-effectiveness analysis to inform efficient allocation of scarce healthcare resources. Costeffectiveness is a relative measure of 'value for money'. Its principal outcome is the incremental cost-effectiveness ratio (ICER), which is benchmarked against thresholds to inform resource allocation decisions (Eichler et al. 2004) . Countries like the UK, Thailand, Australia and Canada have well-known explicit or implicit costeffectiveness thresholds (CETs) for healthcare decision-making (ISPOR 2015) .
However, many other countries including most low-and middleincome countries (LMICs), like Malaysia have not explicitly defined thresholds (Ministry of Health Malaysia 2012; ISPOR 2015) , making translation of cost-effectiveness results into policy recommendations highly subjective. In the absence of locally defined thresholds, analysts often rely on thresholds used in the World Health Organization's CHOosing Interventions that are Cost Effective project (WHO-CHOICE). WHO-CHOICE proposed using thresholds first suggested by the Commission for Macroeconomics and Health (CMH), when conducting global or regional cost-effectiveness analysis (World Health Organization 2001 , 2002 . These thresholds define interventions that cost between one and three times gross domestic product (GDP) per-capita per disability-adjusted life-year (DALY) averted as cost-effective (Edejer 2003; World Health Organization 2015) . However, the 'CMH thresholds' were never intended to be used for national resource allocation (Eichler et al. 2004; Newall et al. 2014; Bertram et al. 2016) , and have been criticized as having major short-comings as a marker for policy making (Newall et al. 2014; Marseille et al. 2015) . Also, the 'CMH thresholds' are easily achieved without consideration of affordability within finite budgets, reducing the negative predictive value of the cost-effectiveness analysis in informing resource allocation decisions (Shillcutt et al. 2009; Newall et al. 2014; Marseille et al. 2015) . Cost-effectiveness analysis has additional benefit in aiding pricing negotiations with pharmaceutical manufacturers (Muangchana et al. 2012; Teerawattananon and Tritasavit 2015) , but the use of CETs that are high in comparison to available budgets reduces their value in this process. Nevertheless, 'CMH thresholds' are still extensively used in LMICs for lack of widely used alternatives (Edejer 2003; Jit et al. 2009; Walker et al. 2010) .
World Health Organization (WHO) economists recently suggested that CMH thresholds should not be used as decision rules for national decision-making. Instead, they propose developing locally defined thresholds based around country considerations including affordability (Bertram et al. 2016) . However, there are few published studies showing how such considerations may be captured in alternative means of determining the cost-effectiveness of interventions (Carvalho et al. 2017 ).
To illustrate the implications of using different CETs in national decision-making, we examine the case study of rotavirus vaccination in Malaysia. Rotavirus is an important cause of diarrheal mortality and morbidity worldwide (Parashar et al. 2009 ). Although rotavirus incidence is similar worldwide ), most deaths occur in low-income countries, with poor access to health care and sub-optimal management of severe diarrhoea (Parashar et al. 2009; Tate et al. 2012) . In Malaysia, an upper middle-income country (UMIC) with a well-established healthcare system (Jaafar et al. 2013) , rotavirus results in few deaths but substantial morbidity, in terms of health and economic burden to households, healthcare providers and society (Loganathan et al. 2015 (Loganathan et al. , 2016b . Although generally regarded as cost-effective interventions in LMICs (Rheingans et al. 2009; Atherly et al. 2012) , rotavirus vaccines are relatively expensive (Nelson et al. 2013; Kotirum et al. 2015) , and are not used in many middle-income countries (MICs) including Malaysia.
Tiered-pricing mechanisms allow profits from the sale of vaccines to high-and MICs to subsidize vaccination for low-income countries (GlaxoSmithKline 2014; Medecins Sans Frontieres 2015) . Eligible low-income countries receive Gavi, the Vaccine Alliance support for vaccines purchased at substantially lower prices (PATH 2015) . Although high-income countries may not have difficulty funding expensive vaccines, high vaccine prices are likely to be a barrier for new vaccine introduction in MICs. Pricing opacity or the lack of transparency in pricing of vaccines offered to different countries, hinders governments from effectively negotiating for more affordable prices (Nelson et al. 2013; Medecins Sans Frontieres 2015; Rappuoli 2015) . Budget constraints (affordability) are cited as a reason MICs fall behind low-and high-income countries in introducing new and potentially lifesaving vaccines that are technically cost-effective under 'CMH thresholds' (Kaddar et al. 2013; Dykstra et al. 2015; PATH 2016) .
In this study, the cost-effectiveness and affordability of a universal rotavirus vaccination programme in Malaysia are explored at different CETs. These thresholds are motivated by fundamental economic theories on resource allocation: (1) the valuation of health on the basis of productivity (human capital), (2) the determination of health needs and its value by consumers of healthcare (consumer sovereignty) and (3) the economic concept of valuing the benefits of the next best intervention foregone (opportunity costs). Cost-effective prices that take such considerations into account are then suggested.
Materials and methods

Overview
Microsoft Excel-based, age-structured, multi-cohort model designed by modellers from several European countries (Jit et al. 2009 Postma et al. 2011) . See Supplementary Text 6 in the Supplementary Appendix for a detailed model description. Multiple cohorts of vaccinated and unvaccinated children, based on the 2012 Malaysian birth cohort of 508 774 live births (Department of Statistics Malaysia 2012b), were followed from birth to the age of 5 years. Cohorts were stratified into monthly age bands for the first year of life and yearly bands subsequently.
The cost-effectiveness outcome was expressed as the ICER and reported in terms of net costs per quality-adjusted life-years (QALY) gained. Net costs were defined as vaccination programme costs less savings from reduced illness post vaccination. Health benefits were estimated for both patients and caregivers.
Two rotavirus vaccines, Rotarix (GlaxoSmithKline, Rixensart, Belgium) and RotaTeq (Merck & Co. Inc., West Point, PA, USA), are recommended by the WHO for universal vaccination (World Health Organization 2013d). The cost-effectiveness of both Rotarix and RotaTeq were considered separately, and from both the healthcare provider and societal perspectives. In the base-case, the costeffectiveness of Rotarix and RotaTeq were evaluated from the healthcare provider's perspective. In alternate scenarios, costeffectiveness of rotavirus vaccines were evaluated from the societal perspective. Waning immunity, no herd immunity and QALY loss for the child and one caregiver was assumed in the base-case. The Pan American Health Organization (PAHO) Revolving Fund vaccine prices were used in the base-case, as the most likely tender price for rotavirus in Malaysia (Ministry of Health Malaysia 2014a; PAHO 2013). The Recommended Retail Price for Malaysia was used as the most likely market price. An annual discount rate of 3% per annum was used (Walker et al. 2010) .
The base year for analysis was 2013. All costs were inflated to 2013 Ringgit Malaysia (RM) using GDP deflators (Department of Statistics Malaysia 2012a) then converted to 2013 US Dollars (US$) using the World Bank exchange rate for 2013 of US$1 for RM 3.15 (World Bank 2014). Analysis was conducted using Microsoft Excel Professional Plus 2013. Assumptions in the base-case and alternative scenarios are presented in Table 1 Table S1 ).
Parameters in the model
Rotavirus incidence and cost of illness Rotavirus incidence was classified into rotavirus episodes requiring home-treatment, outpatient treatment, hospital admission and those resulting in death. Costs were direct medical costs for hospitalizations and outpatient visits from the healthcare provider's perspective, and direct medical, non-medical and indirect costs for all rotavirus episodes from the societal perspective.
A detailed estimation of the health and economic burden of rotavirus diarrhoea in Malaysia has been published (Loganathan et al. 2016b ). This estimation is summarized in the Supplementary Appendix (Supplementary text 1 and 2).
Quality-adjusted life-years DALYs averted and QALYs gained are very different health outcome measures (Robberstad 2005) . DALYs are recommended for use by WHO and World Bank, and are generally used by lowincome countries (World Bank 1993; Edejer 2003) . QALYs are preferred by economists in high-and MICs (Henry et al. 2005; Brazier and Longworth 2011) and are recommended for use by academic groups and many health systems (Ultsch et al. 2015) . The most recent guidance from the WHO on economic evaluation of vaccines recommends using either QALYs or DALYs as appropriate (World Health Organization 2008) . As Malaysia is an UMIC that has used QALYs in most previous economic evaluations (Ministry of Health Malaysia 2012), health outcomes were measured in QALYs in this study to allow for comparability between interventions.
A prospective, community-based Canadian study informed on per-episode health-related quality of life (HRQoL) weights for the child (0.0022) and caregiver (0.0018). HRQoL was measured for children under 3 years of age presenting with diarrhoea at outpatient settings and caregivers (Brisson et al. 2010) . Thus in the base case, HRQoL weights for home-treated episodes were assumed to be 50% of episodes requiring medical care.
The impact of the health of a child on utility of the caregivers is often recommended to be considered in economic evaluations (Griebsch et al. 2005) . Hence, QALY loss was considered for both the child and the primary caregiver in the base-case, while QALY loss was assumed for zero and two caregivers in alternate scenarios. See Supplementary Text 3 in the Supplementary Appendix for details. per-dose of for Rotarix and RotaTeq, were used as the market-price (Ministry of Health Malaysia 2014a). Additional programmatic costs are marginal programmatic costs, including for enhancing vaccine storage and delivery, surveillance, training and advocacy (Edejer 2003) . Estimation of additional programmatic costs of US$4.83 per-dose for rotavirus vaccines are in the Supplementary Appendix.
Costs of the vaccination programme
Vaccine wastage of 5% per-dose was included to the programmatic costs (World Health Organization 2013c) .
Supplementary text 4 in the Supplementary Appendix provides additional detail on the costs of vaccination programmes.
Vaccine coverage
Rotavirus vaccines are likely to be administered together with routine diphtheria, tetanus and pertussis (DTP) vaccines at 2 and 3 months for Rotarix and at 2, 3 and 5 months of age for RotaTeq (World Health Organization 2013d). Thus, rotavirus vaccine coverage was based on third dose DTP coverage of 97% in Malaysia (World Health Organization 2013b).
As the national immunization programme in Malaysia is well established, no step-up in coverage was assumed for rotavirus vaccines (Jaafar et al. 2013) .
Vaccine efficacy
The WHO Strategic Advisory Group of Experts on Immunizations recommends that rotavirus vaccine efficacy could be extrapolated from countries within similar child mortality strata (Strategic Advisory Group of Experts 2009). Malaysia had an under-5 mortality rate of 9 per 1000 live births in 2013 (World Health Organization 2013a), and is categorized in the low-mortality strata. We estimated efficacy for both rotavirus vaccines in Malaysia, based on studies conducted in countries within the low mortality strata. This estimation is detailed in the Suplementary Appendix (Supplementary text 5).
Sensitivity analysis
Sensitivity analysis was performed to assess the robustness of the economic evaluation to variation in key parameters. We conducted univariate and scenario-based sensitivity analysis. During the univariate sensitivity analysis, parameters were varied individually to observe changes in the cost per QALY gained from vaccination, while other parameters were kept constant at base-case assumptions. As vaccination was found to be cost saving in the base case analysis, various pessimistic scenarios that would make the vaccination programme less cost-effective were explored. The sensitivity analysis is detailed in the Supplementary Appendix (Supplementary text 7).
Threshold analysis
Threshold analysis was conducted to inform prices at which vaccination programmes are 'cost-effective' in Malaysia. Threshold prices are vaccine procurement prices below which vaccination programmes are cost-effective. At threshold prices, the net vaccination costs per QALY gained are equal to the CET. CETs for Malaysia were derived using three different approaches: (1) 'CMH thresholds' (human capital); (2) societal willingness-to-pay (WTP) thresholds (consumer sovereignty) and (3) marginal productivity thresholds (opportunity costs). The rationales behind these thresholds are described in the following subsections.
'CMH thresholds' 'CMH thresholds' were motivated by the human capital theory, and are based on the argument that saving a life year creates market income at least equivalent to the average wage (Becker 2007) . The CMH introduced the concept of using a nation's GDP per-capita as a benchmark for cost-effectiveness in health. The Commission recognized health as a cornerstone of human capital development, the basis for individual productivity and a crucial element towards economic development (World Health Organization 2001 , 2002 .
The WHO-CHOICE project aimed to propose packages of interventions at the global and regional level that were divided into three categories. Interventions with cost-effectiveness ratios (in cost per DALY averted) below GDP per-capita per DALY averted are 'very cost-effective', while those between one and three times GDP percapita are 'cost-effective', and those above three time GDP percapita are 'not cost effective' (Edejer 2003; World Health Organization 2015) . These thresholds have since been widely used by others to evaluate the cost-effectiveness of single interventions at the national level, using both DALYs and QALYs to measure health outcomes.
In this study, the 'CMH thresholds' were explored to obtain 'cost-effective' vaccine prices or threshold prices, when net costs per QALY gained were between one and three times the 2013 GDP percapita of Malaysia of US$10 538 (World Bank 2014).
Societal WTP threshold Societal WTP thresholds are based on the principles of consumer sovereignty, asserting that consumers' preferences should determine the allocation of resources and the production of goods and services (McGuire et al. 1988) . Preference elicitations methods, either revealed or stated, are used to assign monetary value to a QALY gained (Ryen and Svensson 2014) .
We used empirical findings from a recent, local study to derive a societal WTP threshold for Malaysia. This cross-sectional study employed contingent valuation methods to determine an average societal WTP of US$9813 per QALY gained in the state of Penang (Shafie et al. 2014 ). This WTP threshold was 0.81 times of the 2013 per-capita GDP of Penang (US$12 173) (Department of Statistics Malaysia 2013). By multiplying this fraction with the 2013 GDP per-capita for Malaysia of US$10 538 (World Bank 2014), a societal WTP threshold of US $8495 per QALY gained was estimated for Malaysia.
Marginal productivity threshold
The concept of opportunity costs is fundamental to health economics. In economic evaluation of healthcare interventions, CETs should ideally reflect opportunity costs of foregone benefits of the next best alternative not implemented (Russell 1992; Palmer and Raftery 1999) . In other words, the CET is the marginal productivity of health systems in generating health (Revill et al. 2014; Woods et al. 2015) .
Researchers at the University of York have developed two different estimations of marginal productivity thresholds for LMICs by studying the health effects of changes in expenditure in healthcare using (1) data from the UK (Woods et al. 2015) , and (2) countrylevel data (Ochalek et al. 2015) .
For the first method, estimates for the UK were extrapolated to other countries. Claxton et al. (2015a) used local level, programme expenditure data from the English National Health Service (NHS), to study the relationship between changes in expenditure for a range healthcare programmes with changes in disease-specific mortality.
This study estimated that the UK's National Institute for Health and Care Excellence (NICE) should use a marginal productivity threshold of £12 936 (US$20 212) per QALY gained, which is lower than the current NICE threshold of £20 000-£30 000 per QALY gained (Claxton et al. 2015a) . Woods et al. (2015) subsequently extended the estimated marginal productivity threshold estimates for the UK to LMICs by using the GDP per-capita of the UK and other countries, income elasticity of the Value of Statistical Life and Purchasing Price Parity. This study estimated marginal productivity thresholds for Malaysia ranging from US$3481 to US$6192 (Woods et al. 2015) .
For the second method, Ochalek et al. (2015) used country-level, cross-sectional and panel data to estimate CETs in LMICs, by studying the effect of changes in healthcare expenditure on mortality (Bokhari et al. 2007; Moreno-Serra and Smith 2015) . This analysis was further developed to reflect changes in healthcare expenditure on morbidity as well as mortality using DALYs (Salomon et al. 2013) , while taking into account a country's healthcare expenditure, GDP per-capita, demography, epidemiology and other factors. Ochalek et al. (2015) estimated marginal productivity thresholds for Malaysia that ranged from US$316 to US$967 per QALY gained using country-level data. These thresholds were substantially lower than those previously estimated by Woods et al. (2015) .
Budget impact analysis
A budget impact analysis was conducted to estimate the financial consequences of universal rotavirus vaccination at different prices to the Ministry of Health (MOH), Malaysia. Although the inputs used were the same as those in the cost-effectiveness analysis, the budget impact analysis was conducted from the healthcare provider's perspective, within a period of 1 year.
We compared the rotavirus vaccine programme costs with the MOH, Malaysia's health budget and estimated vaccine budget in Malaysia. The total operating expenditure of the MOH, Malaysia in 2013 was US$5.60 billion, which included US$1.09 billion in public health expenditure (Ministry of Health Malaysia 2013). We estimated the vaccine procurement costs (the vaccine budget) for 2013 of US$37.8 million by using median unit price of vaccines for Table 2 shows the costs and benefits of vaccination with Rotarix and RotaTeq under base-case assumptions, from the healthcare provider's and societal perspectives. Table 3 shows the ICERs of Rotarix and RotaTeq vaccination programmes at tender and market prices, from both the healthcare provider and societal perspectives.
Results
Base-case analysis
In a cohort of children followed from birth to 5 years, rotavirus gastroenteritis is estimated to result in 205 500 non-fatal episodes, 29 400 hospitalizations and 26 deaths annually in Malaysia. Annually, rotavirus is estimated to cost US$31.7 million to the healthcare provider and US$46.9 million to society.
Annually, Rotarix would prevent 138 700 non-fatal episodes (68%), 24 600 hospitalizations (84%), 21 deaths (84%), and avert 1003 of QALYs lost (78%) from rotavirus gastroenteritis. Rotarix vaccination programme would avert US$26.2 million (83%) and US$36.5 million (78%) of costs to the healthcare provider and society, respectively. Annually, RotaTeq would prevent 125 600 nonfatal episodes (61%), 23 700 hospitalizations (81%), 21 deaths (81%), and avert 949 of QALYs lost (73%) from rotavirus gastroenteritis. The RotaTeq vaccination programme would avert US$25.2 million (79%) and US$34.6 million (74%) of costs to the healthcare provider and society, respectively (Table 2) .
At tender prices, both rotavirus vaccines were cost saving from the healthcare provider's and societal perspectives, using all costeffectiveness definitions (Table 3) .
At market prices using the 'CMH thresholds', Rotarix programmes were cost-effective, but RotaTeq programmes were not cost-effective from the healthcare provider's perspective. Both vaccination programmes were cost-effective from the societal perspective. Using the societal WTP and marginal productivity thresholds, both vaccines were not cost-effective at market price, from the healthcare provider's and societal perspectives (Table 3) .
Sensitivity analysis
During sensitivity analysis, parameters were varied individually to observe changes in the cost per QALY gained from vaccination, while other parameters were kept constant at base case assumptions. Parameters that resulted in the most change in the ICER were direct medical costs, incidence of rotavirus hospitalizations and vaccine efficacy. See Supplementary Figure S3 in the Supplementary Appendix for a tornado graph showing the parameters that result in the most changes in the ICER during the sensitivity analysis.
Also, the ICER was highly sensitive to vaccine price, as both vaccines were cost-saving at tender prices at all CETs, and both vaccines were not cost-effective at market prices, from the societal WTP and marginal productivity thresholds (Table 3) . Table 4 displays results of the threshold and budget impact analysis of Rotarix and RotaTeq. The total vaccine cost of Rotarix and RotaTeq were examined at tender, market and threshold prices, and compared with the 2013 public health and MOH operational budget and the estimated 2013 vaccine budget for Malaysia.
Threshold and budget impact analysis
At tender prices of US$6.50 per-dose, Rotarix vaccination programmes would cost US$11.5 million or about 30% of the vaccine budget, 1% of the public health budget, and 0.2% of the 2013 operating budget of the MOH, Malaysia. At tender prices of US$5.20 per-dose, RotaTeq vaccination programmes would cost US$15.1 million, or about 40% of the vaccine budget, 1.4% of the public health budget and 0.3% of the 2013 operating budget of the MOH, Malaysia.
At market prices of US$44.10, Rotarix vaccination programmes would cost US$50.4 million annually, or 133% of the vaccine budget, 5% of the public health budget and under 1% of the 2013 operating budget of the MOH, Malaysia. At market prices of US$36.70 per-dose, RotaTeq vaccination programmes would cost US$64.0 million annually, or about 170% of the vaccine budget, 6% of the public health budget and 1% of the 2013 operating budget of the MOH, Malaysia (Table 4) .
CMH thresholds
Using the CMH thresholds, Rotarix would be 'cost-effective' below US$52 per-dose and 'very cost-effective' below US$31 per-dose. Although, RotaTeq would be 'cost-effective' below US$31 per-dose and 'very cost-effective' below US$18 per-dose. Annually at costeffective prices, Rotarix vaccination programmes would cost between US$37 to US$58 million, and RotaTeq programmes would cost between US$35 and US$55 million.
At 'CMH thresholds', 'cost-effective' Rotarix vaccination programmes would cost between 97 and 153% of the vaccine budget, while 'cost-effective' RotaTeq vaccination programmes would cost between 93 and 146% of the vaccine budget. Both programmes at these threshold prices would cost between 3 and 5% of the public health budget, and about 1% of the operational budget of the MOH, Malaysia (Table 4) .
Societal WTP threshold
At the societal WTP threshold, Rotarix would be 'cost-effective' below US$29 per-dose and RotaTeq would be 'cost-effective' below US$17 per-dose. Annually at 'cost-effective' prices, Rotarix vaccination programmes would cost about US$35 million, and RotaTeq vaccination programmes would cost about US$33 million. 'Costeffective' vaccination programmes would cost about 88-92% of the vaccine budget, 3% of the public health budget, and under 1% of the 2013 operating budget of the MOH, Malaysia (Table 4) .
Marginal productivity threshold
At the marginal productivity threshold using the Woods et al. (2015) definition, Rotarix would be cost-effective between US$24 and US$27 per-dose, while using the Ochalek et al. (2015) definition, cost-effective prices are approximately US$21 per-dose. Rotarix vaccination programmes would cost between US$30 and US$32 million using the Woods et al. (2015) definition, and about US$27 million using the Ochalek et al. (2015) definition.
At the marginal productivity threshold using the Woods et al. (2015) definition, RotaTeq would be cost-effective when priced between US$14 and US$16 per-dose, while using the Ochalek et al. (2015) definition, cost-effective prices are about US$12 per-dose. RotaTeq vaccination programmes would cost between US$29 and US$31 million using the Woods et al. (2015) definition, and about US$26 million using the Ochalek et al. (2015) definition.
At 'cost-effective' prices using the Woods et al. (2015) definition, Rotarix vaccination programmes would cost about 78-86% of the vaccine budget, and RotaTeq vaccination programmes would cost between 75 and 82% of the vaccine budget. At 'cost-effective' prices using the Ochalek et al. (2015) definition, would cost $70% of the vaccine budget, under 3% of the public health budget, and <0.6% of the 2013 operating budget of the MOH, Malaysia (Table 4) .
Discussion
LMICs face financial constraints in healthcare spending; hence the cost-effectiveness analysis can be useful for prioritizing interventions. However, most LMICs do not have defined CETs which are necessary for transparent and consistent decision-making. As Malaysia has no explicit threshold for cost-effectiveness (Ministry of Health Malaysia 2012), previous analysts have used thresholds based on multiples of GDP per-capita or 'CMH thresholds' as a reference for cost-effectiveness (Ezat and Aljunid 2010; Mohd-Dom et al. 2014; Kamaruddin et al. 2016) . The value of life as determined by the CMH, of one to three times of average income was based on arguments around the market value of an extra year of life in good health, as well as additional non-market benefits of health such as avoiding pain, suffering and loss of leisure time (Newall et al. 2014) . However, these human capital arguments do not reflect the efficiency of spending at the margin of the actual healthcare budget, nor the willingness of society to fund increases to that budget. The use of 'CMH thresholds' for evaluating single interventions within a country assume that governments are willing and able to pay one to three times the GDP of the country on health, which may lead to unsustainable healthcare costs (Shillcutt et al. 2009; Singer 2009; Newall et al. 2014; Marseille et al. 2015) . Hence the need for CETs derived based on local budgetary constraints or societal preferences.
The societal WTP threshold used here was based on the first study to empirically measure individual WTP in Malaysia. However, this study conducted in the island state of Penang, with a wealthier population and different ethnic distribution, is less likely to be representative of the Malaysian population. Also, in the absence of a population-based sampling frame, convenient sampling was performed (Shafie et al. 2014) . We estimated the societal WTP threshold for Malaysia, by adjusting for differences in average wealth using GDP per-capita. Nevertheless, our estimate is much lower than the 'CMH thresholds', and may be useful to inform policy. The societal WTP threshold estimated here was 0.81 times of the 2013 per-capita GDP of Malaysia (Shafie et al. 2014) , and is comparable to that of neighbouring Thailand, with a locally defined threshold of 160 000 Baht or 0.9 times the annual GDP per-capita of Thailand (Teerawattananon et al. 2014) . However, to make a meaningful contribution to resource allocation decisions that reflect population-wide preferences, a nation-wide, representative survey is needed.
Individual valuations of health relates to personal income and not healthcare budgets. Thus, thresholds based on the consumer sovereignty have limited usefulness in conditions of budgetary constraint, as interventions deemed cost-effective may prove to be unaffordable (Revill et al. 2014; Woods et al. 2015) . Woods et al. (2015) 13.9-15.6 28.5-31.0 75-82% 2.6-2.8% 0.5-0.6% Ochalek et al. (2015) 11.9-12. Health systems need to allocate scarce healthcare resources in order to maximize health gains for the population. Costeffectiveness analysis compares the costs and health outcomes of alternative healthcare interventions to aid decision-making. For results of cost-effectiveness analysis to align with aims of population health maximization, CETs should ideally reflect the opportunity costs of health benefits foregone. Marginal productivity thresholds reflect opportunity costs, and were determined in accordance to the health systems goal of population health maximization within budgetary constraints. Woods et al. (2015) utilized estimates of marginal productivity from the UK to extrapolate CETs for other countries. These CETs were a first attempt to inform resource allocation with the aim of population health maximization, and are substantially lower than thresholds previously applied in many countries. The upper bounds of the thresholds for Malaysia are 60% of the GDP per-capita, lower than the societal WTP threshold estimates (80% of the GDP per-capita).
However, thresholds estimated by Woods et al. (2015) rely on assumptions that differences in the consumption value of health and the marginal productivity of health systems in generating health are constant across countries. Also, the NHS in the UK was assumed to be typical of all health systems, in terms of efficiency of health production. These assumptions may lead to bias, which can only be overcome by examining country-level estimates of marginal productivity. Ochalek et al. (2015) used two different approaches on two different types of country-level datasets to estimate a range of countryspecific CETs for LMICs (Moreno-Serra and Smith 2015) . A criticism of these approaches is the assumption that current health spending has immediate, measurable benefits on health outcomes, thus potentially underestimating future improvements of mortality. Although underestimating health benefits may theoretically inflate CET estimates, surprisingly these marginal productivity thresholds fall well below the 'CMH thresholds'. Thresholds estimated by Ochalek et al. (2015) are below 10% of the GDP per-capita for Malaysia.
Although the marginal productivity thresholds estimated by the Woods et al.(2015) and Ochalek et al.(2015) are quite different, the threshold prices obtained are fairly similar. Threshold costs are the sum of vaccine cost savings and health benefits (QALYs Â CETs), divided by total number of children vaccinated annually. In Malaysia, rotavirus gastroenteritis results in few deaths but substantial economic burden in terms of hospitalization costs. Thus, most of the benefits of vaccination are from cost savings rather than QALYs gained, which explains why the threshold prices are relatively insensitive to changes in the CETs.
We demonstrate here that thresholds based on country-level estimates of marginal productivity of current healthcare spending are substantially lower than 'CMH thresholds' and those based on individual WTP. The difference between the societal WTP and the marginal productivity thresholds may suggest that the healthcare budget could be substantially increased to reflect population preferences. That is, revealed preference studies can be used to inform allocative efficiency questions (the level of healthcare funding), rather than productive efficiency questions (whether to fund rotavirus vaccination). In the absence of overall budgetary increases, marginal productivity thresholds could be useful in informing 'cost-effective' prices for rotavirus vaccines. Using the Ochalek et al. (2015) thresholds for Malaysia, we estimate 'cost-effective' rotavirus vaccine prices between US$42-US$44 per-course and US$36-US$37 percourse for Rotarix and RotaTeq, respectively. Rotavirus vaccination programmes would cost around US$26 million or 70% of the estimated vaccine budget and under 2.5% of the MOH public health budget for 2013.
Although tender prices are not known in advance, vaccine prices obtained for national immunization programmes are often substantially lower than market prices. Yet, policy-makers often require CEAs to be conducted at market prices, at which vaccination programmes are seldom cost-effective or affordable. High vaccine prices are a perceived financial barrier for inclusion of rotavirus vaccines in MICs (Nelson et al. 2013; Kotirum et al. 2015) .
Even though, rotavirus vaccine prices for the PAHO Revolving Fund (US$13-15 per-course) (PAHO 2013) and Gavi, the Vaccine Alliance (US$5 per-course) (UNICEF 2016) are in the public domain, and the WHO has established the V3P database to increase vaccine price transparency (World Health Organization 2017), prices negotiated by individual governments are generally not available internationally. Pricing opacity hinders individual governments' efforts for effective price negotiations, and may lead to unregulated differential pricing between countries (Nelson et al. 2013; Medecins Sans Frontieres 2015; Rappuoli 2015) . Although 'reference prices' from other countries are often used, information on value for money and budget impact, that incorporate the costs and benefits of the vaccine in the local context and the magnitude of the burden, have a tangible role in evidence-based price negotiations (Teerawattananon and Tritasavit 2015) . For these reasons, cost-effective prices determined in this study are of practical value to aid future negotiations by Malaysia and other countries.
Rotavirus vaccines are known as cost-effective interventions in LMICs, at low vaccine prices (Rheingans et al. 2009; Tu et al. 2011; Atherly et al. 2012; Kotirum et al. 2015) . Rotavirus vaccination are considered 'very cost-effective' as defined by 'CMH thresholds', in all 72 Gavi-eligible countries as a group and in each country individually (Atherly et al. 2012) . Although deemed a cost-effective intervention in developing countries, vaccine price is the dominant parameter influencing cost-effectiveness (Tu et al. 2011; Kotirum et al. 2015) . Hence, budget constraints rather than cost-effectiveness based on arbitrarily defined thresholds, are more likely to influence rotavirus vaccine introduction (Tu et al. 2011; Newall et al. 2014) .
Notably, there is no benchmark to inform affordability. Affordability is a consensus arrived at by comparing programmatic costs with the healthcare budget, and this can only be definitively determined by the budget holder. A budget impact analysis provides additional information to gauge affordability.
We found that if Malaysia introduced a rotavirus vaccination programme at the PAHO prices, the vaccine budget would have to be increased by about 40%. If this could be a new budget line item rather than displacing existing vaccines, then this would be potentially affordable as it would amount to $1.0% of the public health and 0.2% of the entire MOH operational expenditure. However at market prices, the vaccine budget would have to more than double, which would appear financially challenging. Hence using locally defined thresholds, a publicly financed rotavirus vaccination programme appears more likely to be cost-effective and affordable in Malaysia at prices negotiated in line with international tenders, but not at market prices.
This study has several limitations. First, additional programmatic costs of vaccination programmes were derived by regression analysis of studies conducted at different countries. Although costs of vaccination programmes should ideally be empirically measured (World Health Organization 2014), this was beyond the scope of this study.
Second, the marginal productivity thresholds derived here are based on econometric analysis of health system costs: (1) The Woods et al. (2015) extrapolated the efficiency of health care spending from the English NHS to other countries, (2) Ochalek et al. (2015) applied published mortality estimates to local mortality, life table and morbidity data to estimate thresholds for LMICs. These marginal productivity thresholds only address opportunity costs in terms of health, but not in terms of the loss of wider societal benefits. For each new intervention there are health opportunity costs, as well as costs in terms of societal benefits foregone. Claxton et al. (2015b) estimated that it costs the NHS in the UK £12 936 to produce a QALY, but then each of these QALYs is associated with an estimated £11 611 of wider societal benefit. Thus CETs based on health system opportunity costs are inadequate to evaluate health technologies from a societal perspective.
In addition, we only consider the budget impact of a new vaccination programme within the first year of investment. This may be inadequate, as decision-makers may contemplate borrowing to supplement the healthcare budget. As such, the return of investment of the vaccination programme may be relevant to inform decision makers if future cost savings would be substantial enough to outweigh repayment schedules (Paulden and Claxton 2012) .
If it is assumed than healthcare budgets are efficiently optimized, when a new intervention is introduced, the least cost-effective intervention currently funded is disinvested. However, when a new item consumes a large proportion of the healthcare budget, it is likely to displace a greater number of funded technologies including those not at the margin, and more cost-effective. As such, interventions with higher budget impact would need to be assessed with a 'nonmarginal' threshold, which would be considerably lower than 'marginal' productivity (Paulden et al. 2017) .
Finally, in the absence of local or regional evaluation on the impact of rotavirus on young children, HRQol weights derived from a Canadian study was used in this evaluation (Brisson et al. 2010) . The methodological difficulties of estimating QALYs in children, including the lack of validated measurement tools specifically designed to assess children under the age of 5 years, hamper the conduct of these assessments in Malaysia.
Our study provides cost-effectiveness and budget impact findings at different locally defined CETs that are vital for decision-making. Nonetheless, priority setting in healthcare, particularly for vaccines requires multiple criteria besides cost-effectiveness and affordability, that are not considered here (Kimman et al. 2006; Piso and Wild 2009; Ultsch et al. 2015; Angelis and Kanavos 2016) , including assessment of burden, distributional impact and reduction in out-of-pocket payments that can cause financial hardship to households. (Bä rnighausen et al. 2014; Jit et al. 2015; Loganathan et al. 2016a ).
Conclusion
Our study is one of the first to demonstrate how criticisms of the use of 'CMH thresholds' for national decision-making (Newall et al. 2014; Marseille et al. 2015; Ochalek et al. 2015; Woods et al. 2015; Bertram et al. 2016) , can be reflected in the way microeconomic evaluations for national public health investments are conducted. It is to our knowledge the first study in Malaysia to use alternative thresholds to 'CMH thresholds'. We show that these alternative thresholds can help reach reasonable decisions, inform pricing and tendering decisions, as well as reflect budgetary constraints. At locally defined thresholds, we find that rotavirus vaccines are costeffective at prices in line with international tenders, but not at market prices. Locally defined thresholds that represent marginal productivity of health displaced are likely to be substantially lower than 'CMH thresholds' and those suggested by individual preference measures. This first economic evaluation of rotavirus vaccines for Malaysia suggests that using such considerations can help determine rotavirus vaccine prices that are affordable and productively efficient in the local context. Conversely, revealed preference studies may be used to drive the overall budget allocation for healthcare spending in a manner that is allocatively efficient.
Supplementary Data
Supplementary data are available at Health Policy and Planning online.
